Non-Hodgkin's Lymphoma, Phase III
A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alexis Walker, PA
- Alfredo Axtmayer, APRN
- Armand Russo, MD
- Catherine Wei, MD
- Clarice Grens, APRN
- Elan Gorshein, DO, JD, MPH
- Ethan Kohn, PA
- Francine Foss, MD
- Iris Isufi, MD
- Kayla Martello
- Kristen Hoxie, PA
- Madeline Santiago
- Natalia Neparidze, MD
- Sabrina Browning, MD
- Sara Anastasio, APRN, RN
- Scott Huntington, MD, MPH, MSc
- Stuart Seropian, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Tarsheen Sethi, MD, MSc
- Terri Parker, MD
- Vidya Kesavan
- Virginia Syombathy, APRN
- Yifei Zhang, MD
- Last Updated01/06/2026
- Study IRB#2000036510